-+ 0.00%
-+ 0.00%
-+ 0.00%

EU approves six-week dosing schedule for Regeneron's Libtayo

PUBT·11/17/2026 12:01:09
Listen to the news
EU approves six-week dosing schedule for Regeneron's Libtayo
  • The European Commission cleared extended dosing and shorter infusions for Regeneron’s Libtayo across six approved skin, lung and cervical cancer indications.
  • Patients can receive 700 mg every six weeks over 30 minutes following 12 weeks of 350 mg every three weeks.
  • For 350 mg doses, subsequent infusions can take 15–30 minutes if the first 30-minute infusion was well tolerated.
  • A U.S. supplemental Biologics License Application for the alternative dosing regimen remains under review, with a decision expected in March 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170700PRIMZONEFULLFEED9878947) on November 17, 2026, and is solely responsible for the information contained therein.